Drugs / RLY-8161
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07584226 | Mar 2026 → Dec 2027 expected | melanoma | Relay Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLY-8161 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07584226 ↗ |
| Action | Inhibit | “RLY-8161 is an NRAS-selective inhibitor” NCT07584226 ↗ |
| Route | Oral | “Multiple doses of RLY-8161 for oral administration” NCT07584226 ↗ |
| Target | NRAS | “RLY-8161 is an NRAS-selective inhibitor” NCT07584226 ↗ |